HDAC9 and neuroblastoma: With the knowledge that aberrant HDAC activity drives undesirable phenotypes associated with poor outcomes in NB, we evaluated the chemotherapeutic mechanisms of M344 as an HDAC inhibitor for reversal of HDAC-mediated characteristics in NB.